HR negative + HER-2 positive

Methods We derived a novel PDX from a patient with hormone receptor negative, HER2-positive IBC refractory to neoadjuvant chemotherapy with Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP)...We performed short-tandem repeat (STR) profiling, plotted tumor growth curves for mice treated with alpelisib/everolimus vs. untreated, and immunohistochemistry (IHC), and performed clinical genomic assays...Conclusion We established a PDX of a HER2-positive IBC tumor with a PIK3CA hotspot mutation (H1047R) refractory to TCHP. Targeting the PI3K/mTOR pathway may be useful to overcome resistance in HER2-positive IBC with a H1047R mutation in PIK3CA.

Higher AR expression was associated with improved neoadjuvant treatment response in HER2-positive breast cancer, particularly in the hormone receptor-negative subgroup. However, given the retrospective single-center design and inconsistent findings in the overall population, the clinical value of AR assessment remains preliminary and requires validation in larger prospective studies.

The model was externally validated in an independent cohort of 143 TPBC patients treated between January 2022 and December 2024, and the results demonstrated robust predictive performance and good calibration. This model serves as a tool for early risk stratification in TPBC, thereby facilitating personalized treatment strategies and risk-adapted surveillance to improve patient outcomes.

Chemotherapy was the first-line regimen in 83 of 162 patients (51%), endocrine monotherapy in 55 of 162 (34%), and trastuzumab-pertuzumab-taxane or cyclin-dependent kinase 4 and 6 inhibitor-based regimens in eight of 162 (5%). 87534309); Center for Global Health at the United States-National Cancer Institute at the National Institutes of Health (contract award No. HHSN2612010000871/NO2-PC-2010-00087); Fogarty International Center, NIH, HHS; and Susan G. Komen for the Cure; in Argentina, Instituto Nacional del Cáncer (Ministry of Health), Fundación Argentina de Nanotecnología, Agencia Nacional de Promoción Científica y Tecnológica, CONICET (Ministry of Science, Technology, and Productive Innovation); Brazil, Ministério da Saúde (Ministry of Health); Chile, Instituto de Salud Pública (Public Health Institute) and Ministerio de Salud (Ministry of Health); and Mexico, Consejo Estatal de Ciencia y Tecnología de Jalisco (COECYTJAL) and Universidad de Sonora (University of Sonora).

Current evidence suggests that pregnancy itself does not inevitably worsen breast cancer prognosis when treatment is not compromised. However, breast cancers diagnosed soon after childbirth represent a distinct high-risk subgroup. These findings support full-intensity, guideline-based therapy during pregnancy and highlight the need for special attention and further research focused on postpartum breast cancer.

P1/2, N=29, Suspended, University of Florida | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

Six cycles of docetaxel, trastuzumab, and pertuzumab led to a 59% reduction in the primary tumour and complete radiological resolution of the splenic lesion. Although extremely rare, ISM can present as the initial manifestation of de novo metastatic breast cancer. Awareness of this possibility may facilitate early systemic therapy and obviate the need for diagnostic splenectomy.

In patients with HR-HER2 + EBC, the neoadjuvant therapy with trastuzumab, pyrotinib and dalpiciclib has promising activity and manageable toxicity. Further investigation is needed.

P1/2, N=29, Recruiting, University of Florida | Trial primary completion date: Jun 2025 --> Dec 2025

While curative-intent GCT was associated with improved survival in this Malawian cohort, treatment completion rates were suboptimal. Resource-stratified guidelines must be paired with locally relevant, multilevel implementation strategies to target barriers to treatment completion.

The binding energy range for these ligands against their respective targets was calculated to be between -15 and -5 kcal/mol. Finally, based on general and common rules in medicinal chemistry, we selected 2, 3, 3, and 8 new ligands with high priority for further studies in the EGFR+HER2, ER, NF-κB, and PR classes, respectively.